CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 427 resultados LastUpdate Última actualización 03/10/2022 [12:06:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Página1 de 18 nextPage   por página


BENZALDEHYDE EXTRACTED FROM ROSALES AS FOODSTUFF PRESERVATIVE, ANIMAL-FEED ADDITIVE, AND FOR TREATMENT OF THE COVID-19 VIRUS

NºPublicación: WO2022200833A1 29/09/2022

Solicitante:

2B SHVAT LTD [IL]

Resumen de: WO2022200833A1

Benzaldehyde (C6H5CHO), for example in a form extracted from a pit or seed of a plant of the Rosales order, in a solution of water wherein the benzaldehyde comprises 3%-7% by volume of the solution, and in some embodiments, about 5% is used as a food preservative, an animal feed additive, a treatment and/or preventative treatment for covid-19 coronavirus infections. Please correct.

traducir

COMPOSITIONS, KITS, AND METHODS FOR VARIANT-RESISTANT DETECTION OF TARGET VIRAL SEQUENCES

NºPublicación: WO2022203748A1 29/09/2022

Solicitante:

LIFE TECHNOLOGIES CORP [US]

Resumen de: WO2022203748A1

Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the specific and differential detection of SARS-CoV-2, including SARS-CoV-2 variants, or other coronaviruses from samples including veterinary samples, clinical samples, food samples, forensic sample, an environmental sample (e.g., soil, dirt, garbage, sewage, air, or water), including food processing and manufacturing surfaces, or a biological sample.

traducir

Anti-coronavirus antibodies and methods of use

NºPublicación: AU2021234242A1 29/09/2022

Solicitante:

ABCELLERA BIOLOGICS INC
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

AU_2020435452_PA

Resumen de: AU2021234242A1

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

traducir

COMPOSITIONS AND METHODS FOR RAPID COVID-19 DETECTION

NºPublicación: WO2022204023A1 29/09/2022

Solicitante:

UNIV DUKE [US]

Resumen de: WO2022204023A1

The present disclosure provides compositions and methods related to the detection of pathogenic organisms. In particular, the present disclosure provides compositions and methods related to the detection and/or quantification of viral RNA in a sample from a subject that has, or is suspected of having, a SARS-CoV-2 infection. Using rapid reverse-transcription loop-mediated isothermal amplification (RT-LAMP), the compositions and methods of the present disclosure provide a portable, inexpensive, rapid, and accurate assay platform for detecting and/or quantifying the presence of a pathogenic organism (e.g., SARS-CoV-2) in a patient sample.

traducir

Oral delivery system comprising hydroxychloroquine and/or chloroquine

NºPublicación: AU2021260149A1 29/09/2022

Solicitante:

GLANIS PHARMACEUTICALS INC

Resumen de: AU2021260149A1

An Oral Delivery System (ODS) of the reservoir or plaster or adhesive type for administrating Hydroxychloroquine and/or Chloroquine for the treatment of rheumatoid arthritis, lupus erythematosus, SARS CoV-2, porphyria cutanea tarda for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7- day continuous application.

traducir

Methods of diagnosing and treating viral infections

NºPublicación: AU2021256083A1 29/09/2022

Solicitante:

ALMISHARI IBRAHIM

Resumen de: AU2021256083A1

Diagnosing and treating viral infections. One example is a method of diagnosing absence of severe acute respiratory syndrome 2 (SARS-CoV-2), the method including: isolating a human in a covid-free environment for an isolation period; performing measurements of a core temperature during the isolation period; and if each of the measurements of the core temperature indicate a lack of fever, declaring the human free of SARS-CoV-2. Another example is a method including treating coronavirus in a human by: receiving a core temperature measurement; receiving a test result regarding the SARS-CoV-2 virus; responsive to the human having both fever and the presence of the SARS-CoV-2 virus, submerging the trunk and the legs of the human in water with a surfactant, and the human at least partially submerged for a treatment period of at least three hours; and controlling a temperature of the water during the treatment period.

traducir

Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine

NºPublicación: AU2021256454A1 29/09/2022

Solicitante:

GLANIS PHARMACEUTICALS INC

Resumen de: AU2021256454A1

A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster or adhesive type for administrating Hydroxychloroquine and/or Chloroquine for the treatment of rheumatoid arthritis, lupus erythematosus, SARS CoV-2, porphyria cutanea tarda for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7- day continuous application.

traducir

Immunogenic compositions against severe acute respiratory syndrome coronavirus 2

NºPublicación: AU2021230334A1 29/09/2022

Solicitante:

NEW YORK BLOOD CENTER INC

WO_2021178623_A1

Resumen de: AU2021230334A1

Disclosed herein are immunogenic compositions for the prevention of infection with SARS-CoV-2. The immunogenic compositions comprise polypeptides, RNA, or DNA and are capable of inducing a long-term and broad immune response in a subject.

traducir

Vaccines and uses thereof to induce an immune response to SARS-CoV2

NºPublicación: AU2021220991A1 29/09/2022

Solicitante:

GEOVAX INC

TW_202140794_A

Resumen de: AU2021220991A1

Provided herein are recombinant modified vaccinia Ankara (rMVA) viral vectors comprising heterologous nucleic acid inserts encoding one or more SARS-CoV2 proteins, peptides, or fragments thereof, operably linked to a promoter compatible with poxvirus expression systems that, upon expression, are capable of inducing protective immunity. The compositions can be used in a priming vaccination strategy or in a prime/boost vaccination strategy to provide immunity to SARS-CoV2 and variants thereof.

traducir

Designer peptides and proteins for the detection, prevention and treatment of Coronavirus Disease, 2019 (COVID-19)

NºPublicación: AU2021222039A1 29/09/2022

Solicitante:

UNITED BIOMEDICAL INC

TW_202144384_A

Resumen de: AU2021222039A1

The present disclosure is directed to a relief system for the effective detection, prevention, and treatment of COVID-19, including (1) serological diagnostic assays for the detection of viral infection and epidemiological surveillance, (2) high-precision, site-directed peptide immunogen constructs for the prevention of infection by SARS-CoV-2, (3) receptor-based antiviral therapies for the treatment of the disease in infected patients, and (4) designer protein vaccine containing S1-RBD-sFc. The disclosed relief system utilizes amino acid sequences from SARS-CoV-2 proteins as well as human receptors for the design and manufacture of optimal SARS-CoV-2 antigenic peptides, peptide immunogen constructs, CHO-derived protein immunogen constructs, long-acting CHO-derived ACE2 proteins, and formulations thereof, as diagnostics, vaccines, and antiviral therapies for the detection, prevention, and treatment of COVID-19.

traducir

Corona virus binders

NºPublicación: AU2021217563A1 29/09/2022

Solicitante:

VIB VZW
UNIV GENT
BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN S
DARTMOUTH COLLEGE
KATHOLIEKE UNIVERSITEIT LEUVEN K U LEUVEN R&D
EXEVIR BIO BV
UNIV BRUSSEL VRIJE

Resumen de: AU2021217563A1

The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.

traducir

Methods of preventing and treating COVID-19 infection

NºPublicación: AU2021241498A1 29/09/2022

Solicitante:

HAZAN SABINE

WO_2021194970_A1

Resumen de: AU2021241498A1

A method of preventing COVID-19 infection comprising the steps of: administering hydroxychloroquine; vitamin C; vitamin D; and zinc; and monitoring the individuals condition over a pre-determined amount of time to determine the individual does not become infected with COVID-19. A method of treating an individual infected with COVID-19 comprising the steps of: administering hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc; and monitoring the individual's condition over a pre-determined period of time to determine whether the individual is no longer infected with COVID-19. The methods can further comprise administering ivermectin in and optionally doxycycline.

traducir

Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms

NºPublicación: AU2021236391A1 29/09/2022

Solicitante:

UNIV JOHNS HOPKINS
CAPRICOR INC

AU_2021236385_A1

Resumen de: AU2021236391A1

The present invention relates to modular systems for vaccination against infectious agents that involves the delivery of, e.g., exosome-loaded, antigen-encoding mRNAs to and into cells and tissues of the immunized subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of vaccines, e.g., nucleic acid vaccines, loaded into extracellular vesicles, e.g., exosomes loaded with synthetic mRNAs encoding multiple surface and cytoplasmic antigens of interest, e.g., antigenic polypeptides derived from an infectious virus, e.g., SARS-CoV-2, designed to elicit strong humoral and cellular immune responses due to the simultaneous expression of antigens in their native state and as exosome-associated antigens.

traducir

Selectable marker proteins, expression vectors, for the production of virus-like particles for therapeutic and prophylactic applications

NºPublicación: AU2021236385A1 29/09/2022

Solicitante:

UNIV JOHNS HOPKINS
CAPRICOR INC

AU_2021236391_PA

Resumen de: AU2021236385A1

The present invention relates to engineered selectable marker proteins for recombinant protein expression, as well as novel expression vector designs for achieving high-level recombinant protein expression, and cells transfected therewith as a platform technology for producing extracellular vesicle-based therapeutic or prophylactic compositions, wherein one or more recombinant proteins of interest are displayed on the surface of the extracellular vesicles. As an example, the present invention relates to a virus-like particle composition comprising such extracellular vesicles displaying one or more antigens configured to induce immune responses against SARS-CoV-2.

traducir

USE OF ULINASTATIN IN PREPARATION OF MEDICATION FOR PREVENTING AND TREATING SEVERE COVID-19

NºPublicación: WO2022199050A1 29/09/2022

Solicitante:

GUANGDONG TECHPOOL BIO PHARMA CO LTD [CN]
SHANGHAI PHARMACEUTICALS HOLDING CO LTD [CN]

Resumen de: WO2022199050A1

Provided is the use of ulinastatin in preparation of a medication for preventing and treating severe COVID-19. The medication contains ulinastatin, polygonatum sibiricum polysaccharide, and carboxymethyl schizophyllan.

traducir

USE OF ULINASTATIN IN PREPARATION OF DRUG FOR TREATING NOVEL CORONAVIRUS PNEUMONIA

NºPublicación: WO2022199049A1 29/09/2022

Solicitante:

GUANGDONG TECHPOOL BIO PHARMA CO LTD [CN]
SHANGHAI PHARMACEUTICALS HOLDING CO LTD [CN]

Resumen de: WO2022199049A1

A use of ulinastatin in the preparation of a drug for treating novel coronavirus pneumonia, the drug comprising components such as ulinastatin, geniposidic acid, isosorbide mononitrate, and the drug has a therapeutic effect on novel coronavirus pneumonia and on myocardial damage caused by novel coronavirus.

traducir

ANTIBODIES TO SARS-COV-2

NºPublicación: WO2022204713A2 29/09/2022

Solicitante:

ATRECA INC [US]

Resumen de: WO2022204713A2

Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

traducir

COMPOSITIONS AND METHODS FOR DIAGNOSING VIRAL INFECTIONS INCLUDING COVID-19 AND FOR INFECTION SEVERITY MONITORING AS WELL AS TARGETED DETECTION OF CYTOKINE STORM

NºPublicación: WO2022204416A1 29/09/2022

Solicitante:

VYRIPHARM ENTPR INC [US]

US_2022305145_PA

Resumen de: WO2022204416A1

Compositions and methods for the diagnosis and treatment of infectious diseases, including for the diagnosis and treatment of Cytokine Storm and Cytokine Release Syndrome. The compositions may include a conjugate of a nucleoside analog, a chelator, and a label for use as imaging and therapeutic agents.

traducir

PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION

NºPublicación: WO2022204431A1 29/09/2022

Solicitante:

ANAVEX LIFE SCIENCES CORP [US]
MISSLING CHRISTOPHER U [US]

Resumen de: WO2022204431A1

Provided herein are compositions comprising one or more diphenyl compounds, such as ANAVEX 1066, or its metabolites, or isomers, or salts, for use in treating symptoms of, or preventing an infection by a coronavirus, particularly an infection caused by a SARS-CoV-2 virus.

traducir

TREATMENT OF LONG HAULERS SYNDROME WITH NICLOSAMIDE

NºPublicación: WO2022204397A1 29/09/2022

Solicitante:

FIRST WAVE BIOPHARMA [US]

Resumen de: WO2022204397A1

Disclosed in certain embodiments is a method of treating long-haulers syndrome associated with infection (e.g., Covid-19) comprising administering a therapeutically effective amount of niclosamide or a pharmaceutically acceptable salt thereof to a patient in need thereof.

traducir

TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE DEAMINASE INHIBITOR

NºPublicación: WO2022204126A1 29/09/2022

Solicitante:

CLEVELAND CLINIC FOUND [US]

Resumen de: WO2022204126A1

The present invention provides compositions, systems, kits, and methods for treating a subject with an RNA virus infection (e.g., SARS-CoV-2) by administering or providing a composition comprising a cytidine deaminase inhibitor (e.g., tetrahydrouridine or cedazuridine).

traducir

COMPOSITIONS AND METHODS FOR INHIBITING PROTEOLYTIC ACTIVATION OF VIRUSES

NºPublicación: WO2022203721A1 29/09/2022

Solicitante:

MAJEED MUHAMMED [IN]
NAGABHUSHANAM KALYANAM [US]
MUNDKUR LAKSHMI [IN]

US_2022304947_PA

Resumen de: WO2022203721A1

The present invention discloses use of a composition comprising enriched in bisdemethoxycurcumin, specifically a composition comprising not less than 20% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% curcumin in preventing the activation of viral spike proteins by inhibiting the activity of proteolytic enzymes and in inhibiting the replication and growth of pathogenic viruses, specifically SARS-CoV-2 in mammalian cells. The invention also discloses the potential of the above composition in managing SARS-CoV-2 induced infections.

traducir

SIRNA HAVING MICRORNA-LIKE ACTIVITY FOR PREVENTING OR TREATING COVID-19, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

NºPublicación: WO2022203448A1 29/09/2022

Solicitante:

UNIV KOREA RES & BUS FOUND [KR]

Resumen de: WO2022203448A1

The present invention relates to siRNA having microRNA-like activity for preventing or treating COVID-19, and a pharmaceutical composition comprising same. The siRNA for SARS-CoV-2 according to the present invention was designed by incorporating AGO-CLIP analysis by additionally considering AGO protein accessibility, which was not previously considered in the design of siRNA, to predict the folding structure of the RNA virus and enable the siRNA to accurately effect the target, and targets the conserved region of the SARS-CoV-2. In addition, the siRNA according to the present invention incorporates the seed sequence of miRNA inhibiting pulmonary fibrosis, considered to be a serious problem in SARS-CoV-2, and thus has miRNA-like activity for preventing virus proliferation and inhibiting pulmonary fibrosis. Therefore, the siRNA is expected to be useful as a therapeutic agent that not only inhibits the proliferation of SARS-CoV-2 virus, but can also treat SARS-CoV-2-related diseases.

traducir

DITHIOCARBAMATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS

NºPublicación: WO2022199367A1 29/09/2022

Solicitante:

UNIV BEIJING [CN]

Resumen de: WO2022199367A1

The present invention relates to the technical field of pharmaceutical chemistry, and provides a dithiocarbamate compound and a preparation method therefor, a pharmaceutical composition, and applications. The dithiocarbamate compound provided in the present invention has Mpro inhibitory activity, and can be used in anti-(novel) coronavirus. As a result of an application example, the dithiocarbamate compound provided in the present invention has an inhibitory effect on the Mpro, and the inhibitory effect on the Mpro is dose-dependent, wherein the inhibition rate of the dithiocarbamate compound on the Mpro is 35.5-97.5% at a concentration of 10 μM.

traducir

NOVEL ORAL TREATMENTS FOR COVID-19

Nº publicación: WO2022204224A1 29/09/2022

Solicitante:

UNIV RUSH MEDICAL CENTER [US]

Resumen de: WO2022204224A1

Methods and compositions are provided for the treatment of COVID-19. More particularly, the disclosure relates to pharmaceutical compositions comprising novel agents that inhibit the binding of SARS-CoV-2 spike S1 with human angiotensin-converting enzyme 2 (ACE- 2) on host cells, decrease viral entry, inhibit NF-κB activation, suppress inflammation, reducing or inhibiting the motor and other functional deficits, fever and cardiac abnormalities induced by of SARS-CoV-2 spike S1 exposure. The agents include 4-hydroxybutyrate, prenol, and eugenol, and optionally a wtSPIDAR protein. The methods and compositions are useful for the effects induced by a SARS-CoV-2 variant.

traducir

Página1 de 18 nextPage por página

punteroimgVolver